Horsham, PA - April 22, 2005 - TargetRx, a marketing information services company that assists pharmaceutical companies in effectively selling and marketing their products, announced today that it raised $15 million (U.S.) in Series D funding. This round of financing was led by Quaker BioVentures, with additional investments from new investors Montagu Newhall and Wasatch Advisors, and investments from all previous venture capital investors including New Enterprise Associates (NEA), Domain Associates, and Acacia Venture Partners. The capital will be used to accelerate the Company's growth by expanding its product offerings, which are based on the Company's unique and powerful large-sample normative database of physician attitudes. This will enable TargetRx to enhance its proven ability to deliver actionable solutions to pharmaceutical companies to help them make accurate and timely marketing and sales decisions, ultimately improving the performance of their brands.

This round of funding is the latest momentum indicator from TargetRx, which has enjoyed significant growth since its inception and has achieved greater than 90% renewal of subscriptions with clients so far in 2005. TargetRx expects 2005 revenue commitments to exceed full year 2004 revenue by the second quarter of this year.

"We're pleased that additional leading investment companies have decided to join our outstanding group of current investors," said Michael Luby, President and CEO of TargetRx. "Our Company's goal is to provide pharmaceutical companies with the diagnostic and predictive information that they need to improve sales and marketing effectiveness in this highly competitive and dynamic market. Our clients and investors see the value in our unique database approach to tracking physician attitudes and translating the findings into highly actionable information to support sales and marketing execution. With this additional funding, we're poised to continue our rapid growth."

"TargetRx has zeroed in on the sweet spot for pharmaceutical companies with the way it delivers marketing information services," said Richard Kollender, Principal at Quaker BioVentures. "Given the current climate of the pharmaceutical market, Quaker strategically decided to invest in TargetRx, as the Company provides pharmaceutical companies with an unrivaled breadth and depth of insights to help drive sales and marketing and also accurately predict future sales performance."

"We are enthusiastic to continue to invest in TargetRx because we're excited with the progress the Company has made since our initial seed investment in 2000," said John Nehra, General Partner of New Enterprise Associates. "TargetRx brings critical value to the pharmaceutical industry, as evidenced by its track record of working with the majority of the top thirty pharmaceutical companies."

TargetRx continues to strengthen its leadership team with two additions to its Board of Directors. Richard Kollender joins the Board from the lead investment firm of Quaker BioVentures. He brings valuable pharmaceutical industry insight to the board, having previously worked at GlaxoSmithKline (NYSE: GSK), where he held positions in sales, marketing and worldwide business development. Jim Lim joins the Board from Montagu Newhall Associates, a $200 million venture capital firm that invests in both funds and companies, where he is a Partner. Previously, Mr. Lim was a Director at Commonfund Capital, a fund-of-funds firm that manages nearly $5.5 billion in capital, and prior to that he spent three years as a Pension Fund Manager for Pfizer (NYSE: PFE).

About TargetRx
TargetRx is a marketing information services Company that delivers actionable insight to pharmaceutical companies to help them effectively sell and market their products -- improving the performance of their brands. TargetRx employs a unique database approach to capturing physician attitudes and translating the findings into highly actionable information for its clients. TargetRx has developed a highly predictive, large-sample normative database of physician attitudes that uncovers the "why" behind physician behavior. These insights provide companies with benchmarks for how a product is currently performing, rich diagnostics that identify immediate ways to improve, and powerful forecasts that accurately predict future performance. TargetRx works with the majority of the top 30 pharmaceutical companies in the U.S. For further information, visit www.targetrx.com/press_room